BioCryst Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . BioCryst Pharmaceuticals
BCRX Stock  USD 6.66  0.51  7.11%   
BioCryst Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioCryst Pharmaceuticals' valuation are provided below:
Gross Profit
410.5 M
Profit Margin
(0.01)
Market Capitalization
1.4 B
Enterprise Value Revenue
3.0611
Revenue
599.8 M
We have found one hundred twenty available fundamental signals for BioCryst Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioCryst Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 124 M in 2026. Enterprise Value is likely to rise to about 115.2 M in 2026

BioCryst Pharmaceuticals Total Revenue

544.23 Million

Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 979.9 K, Interest Expense of 119 M or Selling General Administrative of 304.9 M, as well as many indicators such as Price To Sales Ratio of 3.77, Dividend Yield of 0.0 or Days Sales Outstanding of 69.96. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with BioCryst Stock
Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

BioCryst Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets592.2 M564 M275.8 M
Slightly volatile
Short and Long Term Debt Total1 B967.6 M326.1 M
Slightly volatile
Other Current Liabilities136.8 M130.3 M53.2 M
Slightly volatile
Total Current Liabilities193.7 M184.4 M86 M
Slightly volatile
Property Plant And Equipment Net23.9 M22.8 M9.6 M
Slightly volatile
Accounts Payable7.8 M13.4 M10 M
Slightly volatile
Cash67.2 M120.7 M108.4 M
Slightly volatile
Non Current Assets Total82.7 M78.7 M34.4 M
Slightly volatile
Cash And Short Term Investments387.7 M369.2 M206.9 M
Slightly volatile
Common Stock Shares Outstanding249.6 M237.7 M123 M
Slightly volatile
Non Current Liabilities Total973.2 M926.9 M317.3 M
Slightly volatile
Other Current Assets16.6 M15.8 M8.5 M
Slightly volatile
Total Liabilities1.2 B1.1 B402.5 M
Slightly volatile
Property Plant And Equipment Gross38.8 M37 M12.5 M
Slightly volatile
Total Current Assets509.5 M485.3 M241.4 M
Slightly volatile
Short Term Debt56.3 M31.9 M26.3 M
Pretty Stable
Non Currrent Assets Other25.5 M24.2 M8.5 M
Slightly volatile
Common Stock Total Equity2.2 M2.1 M1.2 M
Slightly volatile
Short Term Investments261 M248.6 M86.1 M
Slightly volatile
Common Stock2.5 M2.4 M1.3 M
Slightly volatile
Other Liabilities46.2 K48.6 K3.2 M
Slightly volatile
Current Deferred Revenue1 M1.1 M168 M
Slightly volatile
Property Plant Equipment18.6 M17.7 M8.9 M
Slightly volatile
Other Assets664.1 M632.5 M280.4 M
Slightly volatile
Net Receivables95.5 M90.9 M30.1 M
Slightly volatile
Long Term Debt Total164.3 M156.5 M72 M
Slightly volatile
Capital Surpluse745.7 M1.3 B765.3 M
Slightly volatile
Deferred Long Term Liabilities46.2 K48.6 K2.6 M
Slightly volatile
Short and Long Term Debt35.1 M34.5 M31.4 M
Slightly volatile
Capital Lease Obligations22.1 M14.7 M13.7 M
Slightly volatile
Net Invested Capital303.9 M368 M225.4 M
Slightly volatile
Net Working Capital256.7 M300.8 M163.4 M
Slightly volatile
Capital Stock1.9 M2.4 M1.5 M
Slightly volatile

BioCryst Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization979.9 K1.4 M807.8 K
Slightly volatile
Selling General Administrative304.9 M290.4 M88.5 M
Slightly volatile
Total Revenue544.2 M518.3 M149.3 M
Slightly volatile
Other Operating Expenses547.3 M521.2 M215 M
Slightly volatile
Cost Of Revenue9.2 M11.2 M8.1 M
Pretty Stable
Total Operating Expenses532.2 M506.9 M210.4 M
Slightly volatile
Income Tax Expense2.3 M2.2 M4.6 M
Pretty Stable
Research Development210.9 M200.8 M117.3 M
Slightly volatile
Selling And Marketing Expenses8.7 M15.6 M8.1 M
Slightly volatile
Interest Income17.8 M17 M6.2 M
Slightly volatile
Reconciled Depreciation1.1 M1.4 M911.7 K
Slightly volatile

BioCryst Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow135.8 M129.3 M108.5 M
Slightly volatile
Depreciation979.9 K1.4 M807.8 K
Slightly volatile
Capital Expenditures961 K1 M1.3 M
Pretty Stable
End Period Cash Flow67.6 M122.3 M109.3 M
Slightly volatile
Stock Based Compensation55.9 M58.9 M30.3 M
Slightly volatile
Issuance Of Capital Stock29.1 K30.6 K40.2 M
Slightly volatile
Exchange Rate Changes56.8 K63.9 K69.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.773.9720.206
Slightly volatile
Days Sales Outstanding69.9673.644.3 K
Slightly volatile
Average Payables12.4 M11.8 M12.3 M
Slightly volatile
Stock Based Compensation To Revenue0.160.172.1104
Slightly volatile
Capex To Depreciation0.991.043.0201
Pretty Stable
EV To Sales5.555.8520.7799
Slightly volatile
Payables Turnover2.451.231.4143
Slightly volatile
Sales General And Administrative To Revenue2.481.641.1662
Slightly volatile
Research And Ddevelopement To Revenue0.420.452.6816
Slightly volatile
Capex To Revenue0.00270.00290.0586
Slightly volatile
Cash Per Share1.011.41.2774
Slightly volatile
Days Payables Outstanding3723913.9 K
Slightly volatile
Income Quality0.920.670.7417
Pretty Stable
Intangibles To Total Assets0.00330.00380.0041
Slightly volatile
Current Ratio2.873.033.4359
Slightly volatile
Receivables Turnover3.065.134.2544
Pretty Stable
Capex Per Share0.00590.00630.0159
Slightly volatile
Average Receivables18.8 M28.8 M30.1 M
Very volatile
Revenue Per Share2.061.960.8173
Slightly volatile
Interest Debt Per Share4.34.092.0033
Slightly volatile
Debt To Assets1.621.540.7955
Slightly volatile
Days Of Payables Outstanding3723913.9 K
Slightly volatile
Ebt Per Ebit37.3639.327.5002
Slightly volatile
Quick Ratio2.822.973.4218
Slightly volatile
Net Income Per E B T0.970.921.005
Slightly volatile
Cash Ratio0.710.751.4463
Very volatile
Days Of Sales Outstanding69.9673.644.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.970.921.0317
Slightly volatile
Fixed Asset Turnover21.5320.519.6642
Pretty Stable
Debt Ratio1.621.540.7955
Slightly volatile
Price Sales Ratio3.773.9720.206
Slightly volatile
Asset Turnover0.870.830.3835
Slightly volatile

BioCryst Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap124 M100.4 M106.9 M
Slightly volatile
Enterprise Value115.2 M112.6 M118.1 M
Slightly volatile

BioCryst Fundamental Market Drivers

Forward Price Earnings1250
Cash And Short Term Investments321.1 M

BioCryst Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioCryst Pharmaceuticals Financial Statements

BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1 M
Total Revenue518.3 M544.2 M
Cost Of Revenue11.2 M9.2 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 1.64  2.48 
Research And Ddevelopement To Revenue 0.45  0.42 
Revenue Per Share 1.96  2.06 
Ebit Per Revenue(0.01)(0.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY